Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei

Keyphrases

• Burkholderia Pseudomallei 100%
• Pseudomallei 100%
• Au Nanoparticles (AuNPs) 100%
• Reverse Vaccinology 100%
• Nanoglycoconjugate 100%
• Lipopolysaccharide 66%
• Lethal Challenge 66%
• Melioidosis 66%
• Glycoconjugate Vaccines 66%
• Specific Antibodies 33%
• Subcellular Localization 33%
• Immunogenicity 33%
• Protective Capacity 33%
• Vaccine Development 33%
• Animal Models of Infection 33%
• Preclinical Testing 33%
• Convalescent 33%
• Vaccine Platform 33%
• Gram-negative 33%
• MHC Class II 33%
• Fatal Infection 33%
• Vaccine Design 33%
• Respiratory Infection 33%
• Novel Protein 33%
• Antibody Titer 33%
• High Protein 33%
• Adhesive Behavior 33%
• Transmembrane Domain 33%
• Seroreactivity 33%
• Novel Antigens 33%
• Adhesive Properties 33%
• Glycoconjugates 33%
• Facultative Intracellular Pathogens 33%
• Gold Nanoparticles(AuNPs) 33%
• Burkholderia 33%
• Hcp1 33%
• Lung Colonization 33%
• Protein-polysaccharide Complexes 33%
• Anti-B 33%
• Complex Pathogens 33%
• In Silico Methods 33%
• In Silico Prediction 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Glycoconjugate 100%
• Burkholderia pseudomallei 100%
• Disease 66%
• Infectious Agent 66%
• Lipopolysaccharide 66%
• Melioidosis 66%
• Antibodies 33%
• Infection 33%
• Immunogenicity 33%
• Vaccine Development 33%
• Adhesive Agent 33%
• Respiratory Tract Infection 33%
• Amoxicillin 33%
• Gold Nanoparticle 33%
• Polysaccharide 33%
• Burkholderia 33%

Immunology and Microbiology

• Burkholderia pseudomallei 100%
• Glycoconjugate 100%
• Reverse Vaccinology 100%
• Immunology 100%
• Infectious Agent 66%
• Immunogenicity 33%
• Antibody Titer 33%
• Cellular Distribution 33%
• Major Histocompatibility Complex 33%
• Burkholderia 33%
• Antibodies 33%